Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment
CEO Neil Clark said: “We have made substantial progress considering that closing the £10.4mln fairness
CEO Neil Clark said: “We have made substantial progress considering that closing the £10.4mln fairness